Table 3.
Results of the univariate sensitivity analysis
| Dimension | Sensitivity analysis values | Cost per QALY (GClb vs RClb) |
|---|---|---|
| Distribution for PFS | Exponential | €20,179 |
| Log-logistic | €18,380 | |
| Log-normal | €16,734 | |
| Gamma | €25,386 | |
| Gompertz | €27,512 | |
| Postprogression survival | CLL8 | €23,623 |
| Health state utilities | 95% CI | €25,878 |
| €24,263 | ||
| Drug costs | Rituximab 100 mg: €210.45; | €21,967 |
| Rituximab 500 mg: €1,049.35; | ||
| Obinutuzumab 1,000 mg: €3,430.08 | ||
| Rituximab 100 mg: €210.45; | €18,055 | |
| Rituximab 500 mg: €1,049.35; | ||
| Obinutuzumab: €3,048.96 | ||
| Drug dosea | SmPC | €24,632 |
| Duration of treatmentb | SmPC | €30,589 |
| Cost of adverse events | −20% | €24,750 |
| +20% | €24,927 | |
| Weekly supportive | −20% | €24,517 |
| care costs | +20% | €25,162 |
| Cost of IV | −20% | €24,753 |
| administration | +20% | €24,926 |
| Time horizon | 10 years | €27,376 |
| 15 years | €25,254 | |
| Discount rate | 0% | €21,629 |
| (costs and benefits) | 5% | €27,073 |
Notes:
a
Base case: real dose of the drugs used in the CLL11 trial with maximum vial sharing; sensitivity analysis: the theoretical rituximab dose was considered according to the SmPC, the mean body surface of the patients in the CLL11 trial, and with maximum vial sharing.
b
Base case: duration observed in the CLL11 trial; sensitivity analysis: duration of treatment according to the SmPC.
Abbreviations: CI, confidence interval; CLL, chronic lymphocytic leukemia; GClb, obinutuzumab + chlorambucil; IV, intravenous; PFS, progression-free survival; QALY, quality-adjusted life year; RClb, rituximab + chlorambucil; SmPC, Summaries of Product Characteristics.